Protego Biopharma

San Diego, CA · Founded 2011 · Privately Held (backing)

Developer of a small molecule therapeutics platform designed to reprogram protein folding for the treatment of various systemic amyloid diseases and protein misfolding diseases. Protego Biopharma is based in San Diego, CA and was founded in 2011. Its last reported valuation was $217 million in Mar 2025. It has raised $182 million across 3 recorded rounds; the latest was a $32.9 million early-stage round in Oct 2025.

Last reported valuation
$216.5M
Oct 2026
Priced at
—
Total raised
$182.1M
Last round
Early Stage VC
Oct 2025

Who backs Protego Biopharma?

12 investors
InvestorType
Lightspeed Venture PartnersVenture capital
Johnson & Johnson Innovation - JLABSOther
Digitalis VenturesVenture capital
ForbionVenture capital
Novartis Venture FundOther
Omega FundsPE / buyout
MPM BioImpactVenture capital
Scripps ResearchOther
Droia Ventures—
Small Business Innovation Research and Small Business Technology Transfer Programs—
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Protego Biopharma investors

12 investors are on record for Protego Biopharma, including Lightspeed Venture Partners, Johnson & Johnson Innovation - JLABS, Digitalis Ventures and Forbion. By type, the record holds 4 venture capital firms and 1 private equity firm. The early-stage round in Oct 2025 drew 18 investors.

Free account
More of Protego Biopharma with a free account
  • ·The complete investor list: 12 names
  • ·Watch Protego Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like Protego Biopharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View